drugset / Trial / NCT00449111

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

NCT00449111

Phase 3 Terminated 11 enrolled Organon and Co
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Timeline

Start
2006-03-13
Primary completion
2006-09-30
Completion
2006-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg
Subject Hydrochlorothiazide Unknown 25 mg
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg

Indications